NHS 1-Minute Pembrolizumab Injection 2026: What the New Cancer Jab Actually Means
⚡ Quick Answer
A faster injection of pembrolizumab (Keytruda) is now landing on the NHS. The drug is exactly the same; only the way it gets into you has changed. A 1 to 2 minute jab under the skin replaces the old 30-minute drip. Around 14,000 patients a year in England, across 14 cancer types, are due to benefit. Survival outcomes are not better, just equal. You still need the hospital visit, the bloods, and the same watch on side effects. The win is mainly time saved in the chair.
On 5 May 2026, NHS England announced a quiet but useful change to how a major cancer drug is given. Pembrolizumab, sold under the brand name Keytruda, can now be delivered as a small injection under the skin instead of a half-hour drip into a vein. The medicine is not new. The cancer-fighting action is unchanged. What has changed is the delivery: faster, simpler, and noticeably less time tethered to a chair. For most patients on Keytruda, that adds up to a real quality-of-life gain over a course of treatment.
This guide takes you through what is actually different in 2026, who qualifies, what stays the same, and what you can realistically expect when your trust makes the switch.
What changed on 5 May 2026 exactly
The headline came from a NHS England press release dated 5 May 2026, confirming that the subcutaneous (under-the-skin) form of pembrolizumab is being rolled out across English trusts. The MHRA had already approved it earlier in 2026. NICE then assessed it and priced it as cost-equivalent to the IV form, which made the green light from NHS commissioning straightforward.
The practical change is speed. The drug itself goes in within about one to two minutes. The full hospital visit, including pre-checks and a short observation period, will usually run 45 to 60 minutes rather than the 90 to 120 minutes most patients are used to with the drip. The rollout covers 14 cancer types and is expected to be used by roughly 14,000 new patients a year in England. It also fits a broader pattern. Subcutaneous atezolizumab arrived in 2023, subcutaneous nivolumab in 2025, and now pembrolizumab makes three. PD-1 and PD-L1 immunotherapies are quietly moving from infusion bag to syringe right across UK oncology.
How the injection differs from the IV drip
The most important point first: the molecule is identical. Same drug, same dose, same schedule (usually every three weeks or every six), same monitoring afterwards. Nothing about the immune-mediated cancer effect changes.
⏱ NHS 1-MINUTE INJECTION vs IV DRIP 2026
| Step | IV drip | 1-min jab |
|---|---|---|
| Drug administration | ~30 min | 1 to 2 min |
| Cannula sited | Yes | No |
| Observation period | 15-30 min | 15-30 min |
| Total visit | 90-120 min | 45-60 min |
| Survival outcomes | Standard | Equivalent |
The differences are physical. Instead of a cannula in the back of your hand or your arm, the nurse gives the injection under the skin of your upper thigh or abdomen. The infusion time falls from around 30 minutes to a brisk minute or two. There is no IV line to set up, no flush, no slow drip. The new formulation contains an enzyme called hyaluronidase, which loosens the tissue under the skin just enough to let the antibody disperse properly; without it, the dose simply would not absorb fast enough to work as an injection.
The only genuinely new side effect is local: a small, slightly red, occasionally itchy lump at the injection site. Most patients say it is mild and gone within a day or two. The serious side effects (the immune-related ones like thyroid issues or lung inflammation) are unchanged because the drug is unchanged. If your team was watching for them before, they will keep watching for them now.
Which 14 cancer types qualify in 2026
The injection is licensed for the same 14 cancer types as the IV version. The list spans:
- Melanoma (skin cancer)
- Non-small-cell lung cancer
- Head and neck cancers
- Urothelial (bladder) cancer
- Oesophageal cancer
- Renal cell (kidney) cancer
- Cervical cancer
- Triple-negative breast cancer
- Classical Hodgkin lymphoma
- Gastric (stomach) cancer
- Endometrial (womb) cancer
- Hepatocellular (liver) cancer
- Cancers with the MSI-H genetic marker
- Plus one further indication depending on licence detail
Important caveat: having one of these cancers does not automatically qualify you for pembrolizumab. Eligibility is still set by NICE and depends on factors like cancer stage, PD-L1 protein expression on biopsy, and whether you have already had other treatment lines. The injection rollout does not change those rules. If you were eligible on the IV form, you will be eligible on the injection. If you were not, the injection alone does not open the door.
What this does NOT change
Worth being honest. The new injection is not a treatment breakthrough; it is a delivery improvement. The drug works exactly as well as before, which clinical trials describe as non-inferior to the IV form. Not stronger, not weaker, the same.
⚠️ KEEP IN MIND
- Survival outcomes are equivalent to the IV form, not better
- This is not a cure – pembrolizumab works for some patients, not all
- You still need hospital visits every 3 or 6 weeks
- Blood tests, scans and oncology reviews continue as before
- NICE eligibility criteria are unchanged
- 1-minute refers to drug delivery time, not the whole appointment
It is also not a cure. Pembrolizumab works well for some patients and not at all for others, and your oncology team will keep checking scans to see how your tumour is responding. Hospital visits continue on the same schedule. You will still have blood tests, oncology reviews, and any scans your team has planned. If your treatment plan includes surgery, radiotherapy, or chemotherapy alongside the immunotherapy, those still go ahead as before. The benefit, properly framed, is that you spend less time in the treatment chair on each visit. Phrases like “life-changing jab” in the headlines refer to the time saving, not to a change in life expectancy. Useful to keep that distinction in mind, especially when worried family members ask.
Side effects and the new local reaction
Side effects fall into two categories. The familiar ones come with the drug and do not change with the injection: tiredness, skin rash, itching, diarrhoea, joint or muscle aches. Less commonly but more importantly, there are immune-mediated reactions. These can affect the thyroid (under- or over-active), lungs (pneumonitis, presenting as a dry cough or breathlessness), bowel (colitis, presenting as persistent diarrhoea or bleeding), or liver (hepatitis, picked up on bloods). Your team will brief you on red flags, and they take any of those signs seriously.
The new side effect, unique to the injection, is a local reaction where the needle went in: redness, a small lump, mild swelling, sometimes itching. It tends to be on the upper thigh or the abdomen. Most reactions settle on their own inside a day or two and need nothing more than a clean shirt and a bit of patience. Severe local reactions are uncommon. Your chemo nurse will show you exactly what to watch for and when to ring the chemotherapy advice line.
Realistic UK patient experience: what your day looks like
Visit day will feel familiar but distinctly shorter. You arrive at the chemotherapy day unit, your bloods are reviewed (if taken that morning or the day before), and you may see an oncologist or specialist nurse for a quick check. Instead of having a cannula sited, the nurse cleans a patch of skin on your thigh or tummy and gives a single injection over one to two minutes. You then sit in the unit for a short observation period, typically 15 to 30 minutes, the same as you would after the drip.
The full appointment usually lands around 45 to 60 minutes, compared to the 90 to 120 minutes most patients are used to. Over a two-year treatment course of roughly 35 visits, that adds up. If you are on a combination regimen, say pembrolizumab with chemotherapy, only the pembrolizumab part becomes the quick jab; you still need a treatment chair and a drip for the chemo. Devolved nations: NHS Scotland is expected to follow within four to six months via the SMC, with NHS Wales (AWMSG) and Northern Ireland (DoH) on a similar timeline, based on what happened with subcutaneous nivolumab in 2025.
Frequently Asked Questions
Is the 1-minute injection less effective than the IV drip?
No. The phase 3 MK-3475A-D77 trial (results presented at ESMO 2024) showed the subcutaneous form is non-inferior to the IV form in non-small-cell lung cancer, with comparable pharmacokinetics, response rates, and survival. In plain terms: same drug levels in the blood, same outcomes. You are not getting a weaker treatment for the sake of convenience.
Does it hurt more than the drip?
It is a different sensation. Most patients describe a brief sharp scratch or stinging during the injection that fades within seconds. The drip involves siting a cannula, which some find more uncomfortable than the actual injection. Soreness or a small lump at the site afterwards is usually mild and temporary. Paracetamol is fine if you want to take the edge off.
Can I have the injection at home?
Not at the moment. The reason is the short observation period afterwards to watch for any acute reactions, which still needs a clinical setting. So your appointment continues in the hospital chemotherapy or day unit. Home administration may come later for selected patients, but it is not on the table for the 2026 rollout.
Which 14 cancers exactly are covered in 2026?
Melanoma, non-small-cell lung cancer, head and neck cancers, urothelial (bladder) cancer, oesophageal cancer, renal cell (kidney) cancer, cervical cancer, triple-negative breast cancer, classical Hodgkin lymphoma, gastric cancer, endometrial cancer, hepatocellular (liver) cancer, and tumours with the MSI-H genetic marker. Eligibility for each cancer type is set by NICE and depends on stage, biomarker status, and prior treatment history.
When will my local hospital switch?
The rollout is phased through May to autumn 2026. Trusts need brief staff training on the injection technique, plus stock and pharmacy workflow adjustments. Most English hospitals are expected to be offering the injection by the end of 2026. If you are on IV pembrolizumab now, ask your chemotherapy advice line or oncology nurse when your trust plans to switch. There is no clinical risk in continuing with the IV form in the meantime.
Is the new injection available in Scotland, Wales, and Northern Ireland?
Not yet. NHS England is leading. The Scottish Medicines Consortium, All Wales Medicines Strategy Group, and the Department of Health Northern Ireland each run their own assessments. Based on the 2025 timeline for subcutaneous nivolumab, the devolved nations typically follow within four to six months. Ask your local oncology centre for an updated date.
I am on pembrolizumab plus chemo, does the chemo also become an injection?
No. Only the pembrolizumab portion of your regimen changes to the quick injection. Chemotherapy drugs are completely separate medicines with their own administration rules; most still need an IV line and a chair. If you are on a combination regimen, expect the chemo part of your day to look exactly the same as before.
Why is it called a 1-minute jab when the visit still takes nearly an hour?
The “one minute” refers to drug delivery time, which is a real drop from the 30-minute infusion. The rest of your appointment (pre-checks, the injection itself, and the safety observation afterwards) still needs time. So your total visit shortens to around 45 to 60 minutes rather than 90 to 120, but the “1 minute” headline is specifically the drug-administration step.
✅ The verdict
The honest summary: this is a meaningful UK quality-of-life improvement for thousands of cancer patients, not a survival breakthrough. Same effective drug, faster delivery, fewer hours spent tethered to a drip. The cancer itself, the schedule, and the side effect picture are essentially unchanged. If you are on pembrolizumab now, ask your oncology nurse when your trust will switch over and whether there is anything you should know about the injection-site reaction.
If you are starting pembrolizumab in 2026, you will likely receive the injection by default by the second half of the year. For trusted UK information, stick with the NHS website, Cancer Research UK, Macmillan Cancer Support, and your own oncology team. They will know your local timeline better than any headline. You can also read about the NHS UK guide to pembrolizumab injection treatment time changes, the 2026 NHS Mounjaro expansion for BMI 35 plus four conditions, or the 2026 NICE semaglutide guidance for heart-disease patients for more on recent NHS treatment updates.
This article is informational only and does not replace personalised advice from your GP, pharmacist, or another qualified healthcare professional.
